BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14686494)

  • 1. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
    Tamaki H; Mishima M; Kawakami M; Tsuboi A; Kim EH; Hosen N; Ikegame K; Murakami M; Fujioka T; Masuda T; Taniguchi Y; Nishida S; Osumi K; Soma T; Oji Y; Oka Y; Kawase I; Sugiyama H; Ogawa H
    Int J Hematol; 2003 Nov; 78(4):349-56. PubMed ID: 14686494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias.
    Kreuzer KA; Saborowski A; Lupberger J; Appelt C; Na IK; le Coutre P; Schmidt CA
    Br J Haematol; 2001 Aug; 114(2):313-8. PubMed ID: 11529849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time reverse transcription loop-mediated isothermal amplification for rapid and simple quantification of WT1 mRNA.
    Morishita S; Tani H; Kurata S; Nakamura K; Tsuneda S; Sekiguchi Y; Noda N
    Clin Biochem; 2009 Apr; 42(6):515-20. PubMed ID: 19297684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
    Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML.
    Kim YJ; Kim DW; Lee S; Kim HJ; Kim YL; Hwang JY; Oh IH; Park YH; Lee YK; Min CK; Kim TG; Han TH; Min WS; Kim CC
    Eur J Haematol; 2002 May; 68(5):272-80. PubMed ID: 12144533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
    Inoue K; Sugiyama H; Ogawa H; Nakagawa M; Yamagami T; Miwa H; Kita K; Hiraoka A; Masaoka T; Nasu K
    Blood; 1994 Nov; 84(9):3071-9. PubMed ID: 7949179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.
    Ogawa H; Tamaki H; Ikegame K; Soma T; Kawakami M; Tsuboi A; Kim EH; Hosen N; Murakami M; Fujioka T; Masuda T; Taniguchi Y; Nishida S; Oji Y; Oka Y; Sugiyama H
    Blood; 2003 Mar; 101(5):1698-704. PubMed ID: 12406915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
    Chen ZX; Kaeda J; Saunders S; Goldman JM
    Chin Med J (Engl); 2004 Jul; 117(7):968-71. PubMed ID: 15265366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time quantitation of bcr-abl transcripts in haematological malignancies.
    Saffroy R; Lemoine A; Brézillon P; Frénoy N; Delmas B; Goldschmidt E; Souleau B; Nedellec G; Debuire B
    Eur J Haematol; 2000 Oct; 65(4):258-66. PubMed ID: 11073166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.
    Nowakowska-Kopera A; Sacha T; Florek I; Zawada M; Czekalska S; Skotnicki AB
    Leuk Lymphoma; 2009 Aug; 50(8):1326-32. PubMed ID: 19811333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction.
    Koizumi Y; Furuya D; Endo T; Asanuma K; Yanagihara N; Takahashi S
    Int J Hematol; 2018 Feb; 107(2):230-234. PubMed ID: 28994041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
    Goh HG; Lin M; Fukushima T; Saglio G; Kim D; Choi SY; Kim SH; Lee J; Lee YS; Oh SM; Kim DW
    Leuk Lymphoma; 2011 May; 52(5):896-904. PubMed ID: 21338281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients.
    Cilloni D; Gottardi E; De Micheli D; Serra A; Volpe G; Messa F; Rege-Cambrin G; Guerrasio A; Divona M; Lo Coco F; Saglio G
    Leukemia; 2002 Oct; 16(10):2115-21. PubMed ID: 12357365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.